Literature DB >> 3473692

Neurologic disease as the presenting manifestation of acquired immunodeficiency syndrome.

J R Berger, L Moskowitz, M Fischl, R E Kelley.   

Abstract

Neurologic disease was the harbinger of the acquired immunodeficiency syndrome (AIDS) in 26 (20%) of 132 patients and ultimately developed in 83 (63%). The most common neurologic disorder heralding AIDS was toxoplasmic encephalitis (17 cases) followed by cryptococcal meningitis (six), retinitis (three), progressive multifocal leukoencephalopathy (two), neuropathy (one), myopathy (one), and subacute "viral" encephalitis (one). In four patients, more than one neurologic disorder coexisted at presentation. Recognition of underlying human T cell lymphotropic virus type III (HTLV-III) infection may allow a more expedient determination of the cause of the neurologic disease. Our study emphasizes the importance of testing for the presence of HTLV-III antibody and assessing the immunologic status of all patients at risk for AIDS who have neurologic illness.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3473692     DOI: 10.1097/00007611-198706000-00004

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  16 in total

1.  Clinical programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection.

Authors:  M A Jacobson; C L Besch; C Child; R Hafner; K Muth; L Deyton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

2.  Polymicrobial central nervous system infection in the acquired immunodeficiency syndrome.

Authors:  A D Sperber; M Alkan; S Stemmer; L Avnon; F Schlaeffer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

3.  Effect of progression of disease on cognitive performance in HIV/AIDS.

Authors:  Francis Odiase; Olubunmi Ogunrin; Adesola Ogunniyi
Journal:  J Natl Med Assoc       Date:  2006-08       Impact factor: 1.798

4.  Quantification of cerebrospinal fluid lactic acid in the differential diagnosis between HIV chronic meningitis and opportunistic meningitis.

Authors:  Sérgio Monteiro de Almeida; Kátia Boritza; Laura Lucia Cogo; Luis Pessa; João França; Indianara Rota; Marisol Muro; Cléa Ribeiro; Sonia Mara Raboni; Luine Rosele Vidal; Meri Bordignon Nogueira; Ronald Ellis
Journal:  Clin Chem Lab Med       Date:  2011-02-11       Impact factor: 3.694

5.  Diagnostic value of stereotactic biopsy of cerebral lesions in patients with AIDS.

Authors:  F Alesch; C Armbruster; H Budka
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

6.  Neurocognitive impairment associated with predominantly early stage HIV infection in Abuja, Nigeria.

Authors:  Christopher Akolo; Walter Royal; Mariana Cherner; Kanayo Okwuasaba; Lindsay Eyzaguirre; Ruxton Adebiyi; Anya Umlauf; Terence Hendrix; Joyce Johnson; Alashl'e Abimiku; William A Blattner
Journal:  J Neurovirol       Date:  2014-06-14       Impact factor: 2.643

Review 7.  [Progressive multifocal leukoencephalopathy].

Authors:  J C Wasmuth; A Wasmuth-Pietzuch; U Spengler; J K Rockstroh
Journal:  Med Klin (Munich)       Date:  1999-05-15

8.  Analysis of oligoclonal antibody bands against individual HIV structural proteins in the CSF of patients infected with HIV.

Authors:  R Kaiser; R Dörries; W Lüer; S Poser; H D Pohle; K Felgenhauer; V ter Meulen
Journal:  J Neurol       Date:  1989-03       Impact factor: 4.849

9.  Phylodynamic analysis of human immunodeficiency virus type 1 in distinct brain compartments provides a model for the neuropathogenesis of AIDS.

Authors:  Marco Salemi; Susanna L Lamers; Stephanie Yu; T de Oliveira; Walter M Fitch; Michael S McGrath
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat.

Authors:  Teresa G D'Aversa; Karl O A Yu; Joan W Berman
Journal:  J Neurovirol       Date:  2004-04       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.